Oscar Health, Inc. (OSCR) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Oscar Health, Inc. is a healthcare technology company operating as a single reportable segment, primarily selling insurance through federal and state ACA exchanges. As of September 30, 2025, the Company reported approximately 2.1 million effectuated members, representing a 28% increase year-over-year. In May 2025, the Company acquired three businesses (INSXCloud, IHC Specialty Benefits, and Healthinsurance.org) to expand its individual market capabilities.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $2,985,984 | $2,423,482 | $8,896,192 | $6,785,128 |
| Premium Revenue | $2,923,968 | $2,368,257 | $8,723,233 | $6,626,055 |
| Net Income (Loss) | $(137,484) | $(54,388) | $(90,469) | $179,406 |
| EPS (Basic/Diluted) | $(0.53) | $(0.22) | $(0.35) | $0.75 / $0.65 |
| Medical Loss Ratio (MLR) | 88.5% | 84.6% | 84.8% | 79.5% |
| SG&A Expense Ratio | 17.5% | 19.0% | 17.3% | 19.0% |
| Cash & Equivalents | $2,148,865 | N/A | N/A | N/A |
| Long-Term Debt | $686,294 | N/A | N/A | N/A |
Note: Q3 2024 EPS was $(0.22) basic and diluted. 9M 2024 EPS was $0.75 basic and $0.65 diluted.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 23% in Q3 and 32% for the nine months ended September 30, 2025, driven primarily by a 28% increase in membership.
- Profitability Decline: The Company reported a net loss of $137.5 million in Q3 2025, compared to a loss of $54.4 million in Q3 2024. This contrasts with a net income of $179.4 million for the same period in 2024. The loss was driven by a significant increase in the net risk adjustment transfer accrual and higher medical costs.
- Medical Loss Ratio (MLR): MLR increased to 88.5% in Q3 2025 from 84.6% in Q3 2024. Management attributes this to increased average market morbidity and higher risk adjustment transfer accruals, partially offset by favorable prior period development.
- Debt Issuance: In September 2025, the Company issued $410.0 million in 2.25% Convertible Senior Subordinated Notes due 2030. Concurrently, the Company terminated its $115.0 million Revolving Credit Facility, which had no outstanding borrowings.
- Debt Conversion: In October and November 2025, holders of the 2031 Notes exercised conversion rights. Dragoneer exchanged $187.5 million of 2031 Notes for approximately 23.3 million shares of Class A common stock.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted that while membership growth was strong, the financial results were impacted by higher-than-expected market morbidity, leading to increased risk adjustment payables. The SG&A expense ratio improved to 17.5% due to fixed cost leverage and disciplined cost management.
Regulatory Risks:
- APTC Expiration: Enhanced Advanced Premium Tax Credits (APTCs) are set to expire at the end of 2025 unless renewed by Congress. Non-renewal could reduce marketplace participation and affordability.
- Program Integrity Rules: New CMS rules regarding eligibility verification and enrollment periods are in effect, though some provisions are currently stayed by litigation. These rules may reduce enrollment volumes.
- One Big Beautiful Bill Act (OBBBA): Recent legislation limits APTC eligibility for certain populations and requires additional verification, potentially reducing the member base.
Unusual Items:
- Risk Adjustment Estimates: In July and September 2025, the Company significantly increased its risk adjustment transfer estimates based on updated third-party market risk score data, negatively impacting revenue recognition.
- CSR Settlement: The Company recorded an estimated net recovery of $49 million related to the Cost-Sharing Reduction (CSR) subsidy settlement.
Investor Verification Checklist
- Risk Adjustment Sensitivity: Verify the stability of the Company's risk adjustment estimates, as recent updates significantly impacted Q3 results and could recur.
- APTC Renewal Status: Monitor legislative developments regarding the renewal of enhanced APTCs, as expiration poses a material risk to membership retention and revenue.
- Debt Conversion Impact: Assess the dilution impact from the recent conversion of $187.5 million of 2031 Notes into equity.
- Medical Cost Trends: Review the drivers of the increased MLR (88.5%) to determine if this is a temporary anomaly or a structural shift in member morbidity.
- Liquidity Position: Confirm that the $2.1 billion in cash and equivalents is sufficient to cover the $1.77 billion in risk adjustment transfer payables and other obligations without further capital raises.